Myriad Genetics (MYGN) said late Monday it has named Chief Operating Officer Sam Raha as chief executive and president, effective April 30, succeeding Paul Diaz.
Diaz, who is leaving to become a managing partner at private-equity firm Cressey, will continue serving as consultant to Raha.
Myriad said that Chief Commercial Officer Mark Verratti will be promoted to COO and that it will hire a new chief commercial officer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.